This is an international site for Exjade® (Deferasirox) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional I am a patient inside of the US I am a patient outside the U.S.

Home > Aplastic and Other Anemias > Overview
Print
Aplastic and Other Anemias

EXJADE Removes Excess Iron in Transfusion-dependent Aplastic and
Other Anemias

In addition to the more common anemias, rare forms of acquired or inherited anemias also require multiple blood transfusions, either to provide effective treatment or offer relief from painful symptoms. However, excess iron that accumulates from these transfusions may lead to iron toxicity.1,2,3

These rare anemias include but are not limited to:

Learn more about how EXJADE reduces toxic iron in patients with:

Aplastic anemia Diamond-Blackfan anemia Sideroblastic anemia Myelofibrosis Fanconi's anemia

Patients with rare anemias have short survival time, with an average of 5 to 10 years from diagnosis, although this is highly dependent upon the therapy a patient receives.

Once a rare anemia is diagnosed, treatment can involve multiple transfusions in a short period of time, resulting in iron toxicity. Many of these patients could benefit from chelation therapy.1

Categorizing other anemias and identifying iron toxicity

Identify patient characteristics and standard iron toxicity tests to evaluate risk.

Learn more

EXJADE efficacy demonstrated across anemias

Clinical studies with EXJADE have demonstrated chelation benefits (serum ferritin levels and liver iron concentration) in patients with aplastic and other anemias.

Learn more

References

  1. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115(2):239-252.
  2. Roggero S, Quarello P, Vinciguerra T, et al. Severe iron overload in Blackfan-Diamond anemia: A case-control study. Am J Hematol. 2009;84(11):729-732.
  3. Beutler E, Victor Hoffbrand AV, Cook JD. Iron deficiency and overload [Am Soc Hematol Educ Program]. Hematology. 2003:40-61.
  4. Hoffman R, Benz E, Shattil S, et al. Hematology: Basic Principles and Practice. 4th ed. Philadelphia, PA: Elsevier; 2005.

WHAT IS EXJADE?

EXJADE is a once-daily oral
iron-chelator.

Learn more
HOW ARE DIFFERENT
ORGANS AFFECTED
BY IRON TOXICITY?

Excess iron from
transfusions can cause
serious consequences
in vital organs.

Learn more
TRANSFUSION-DEPENDENT
β-THALASSEMIA		 MYELODYSPLASTIC SYNDROMES SICKLE CELL DISEASE APLASTIC AND OTHER ANEMIAS TOOLS AND RESOURCES ALL ABOUT EXJADE

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with β-thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusion in patients aged 2 years and older with β-thalassemia major or other anemias when deferoxamine is contraindicated or inadequate.
Disclaimer: This is an international website for Exjade, and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
© Novartis AG | Use of this website is subject to our Terms of Use | About Novartis Oncology | Privacy | Site Map | Contact Us | EU SmPC | Safety Information | PubMed